IPO
Coverage Timeline
newest firstAll Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
IPO
Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined
Biotech IPOs Are Pricing Above Range Again
BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.
BY THE NUMBERS